- Home
- TRIB vs SYBX Comparison
TRIB vs SYBX Comparison
Compare TRIB & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- SYBX
- Stock Information
- Founded
- TRIB 1992
- SYBX N/A
- Country
- TRIB Ireland
- SYBX United States
- Employees
- TRIB N/A
- SYBX N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- TRIB Health Care
- SYBX Health Care
- Exchange
- TRIB Nasdaq
- SYBX Nasdaq
- Market Cap
- TRIB 13.0M
- SYBX 13.6M
- IPO Year
- TRIB N/A
- SYBX N/A
- Fundamental
- Price
- TRIB $0.65
- SYBX $1.26
- Analyst Decision
- TRIB
- SYBX
- Analyst Count
- TRIB 0
- SYBX 0
- Target Price
- TRIB N/A
- SYBX N/A
- AVG Volume (30 Days)
- TRIB 2.4M
- SYBX 7.8K
- Earning Date
- TRIB 08-13-2025
- SYBX 08-07-2025
- Dividend Yield
- TRIB N/A
- SYBX N/A
- EPS Growth
- TRIB N/A
- SYBX N/A
- EPS
- TRIB N/A
- SYBX 0.21
- Revenue
- TRIB $61,555,000.00
- SYBX N/A
- Revenue This Year
- TRIB $13.51
- SYBX N/A
- Revenue Next Year
- TRIB $13.14
- SYBX N/A
- P/E Ratio
- TRIB N/A
- SYBX $5.82
- Revenue Growth
- TRIB 8.31
- SYBX N/A
- 52 Week Low
- TRIB $0.48
- SYBX $0.90
- 52 Week High
- TRIB $3.44
- SYBX $1.88
- Technical
- Relative Strength Index (RSI)
- TRIB 48.68
- SYBX 52.81
- Support Level
- TRIB $0.60
- SYBX $1.17
- Resistance Level
- TRIB $0.87
- SYBX $1.27
- Average True Range (ATR)
- TRIB 0.08
- SYBX 0.04
- MACD
- TRIB 0.01
- SYBX -0.01
- Stochastic Oscillator
- TRIB 33.94
- SYBX 40.00
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.